Table 1:

Patient demographics, MRI data

	≤10 years		All
	mTOR	Controls	mTOR	Controls
Number of participants	8	14	17	24
Sex (%male)	75	50	71	54
Age, mean (SD) (years)	9.1 (1.8)	7.8 (2.2)	12.8 (4.7)	14.7 (9.0)
Age range (years)	[3.5, 10.87]	[37, 107]	[3.5, 25.7]	[3.7, 44.3]
Duration of treatment, mean (SD) (years)*	3.4 (1.6)	-	3.5 (2.3)	-
Serum levels, mean (SD) (ng/mL)	5.7 (1.9)	-	5.8 (2.6)	-
% Maximum SEGA volume decrease, mean(SD)	50.8 (20.1)	-	50.8 (19.6)	-
Number of scans	31	18	76	49
Number of scans per participant, mean (SD)	4.1 (2.2)	1.3 (0.6)	4.5 (3.0)	2.0 (1.04)
Number of DWI volumes removed, mean (SD)	0.4 (1.2)	0.2 (0.7)	0.3 (0.9)	0.4 (1.3)
Number of participants with 1 scan	1 (12.5%)	11 (79%)	5 (29%)	7 (29%)
Number of participants with 2 scans	1 (12.5%)	2 (14%)	1 (6%)	13 (55%)
Number of participants with 3 scans	1 (12.5%)	1 (7%)	2 (12%)	1 (4%)
Number of participants with 4 scans	1 (12.5%)	0	0	2 (8%)
Number of participants with 5 or more	4 (50%)	0	9 (53%)	1 (4%)

mTOR patients on everolimus, an inhibitor of the mechanistic target of rapamycin; SEGA subependymal giant cell astrocytoma; DWI diffusion weighted imaging